Biotechnology

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.

Teva says patients taking Ajovy experienced a significant reduction in migraine days compared to those receiving placebos.

I dub Resonant and Chiasma as 'busted IPOs'.

In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk 'related to intravenous infusion ports and renal toxicity,' the company says.

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

For those with a long-term horizon, here are some top picks.

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.

Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.